Unlock instant, AI-driven research and patent intelligence for your innovation.

Human parathyroid hormone medicine composition

A technology of parathyroid hormone and composition, which is applied in the direction of drug combination, drug delivery, and pharmaceutical formulation, and can solve problems such as instability

Inactive Publication Date: 2005-04-27
ELI LILLY & CO
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because it is a protein, it is very unstable compared to traditional small molecular weight drugs, however, parathyroid hormone formulations face challenges not often encountered by the pharmaceutical industry

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] 0.1 mg rhPTH(1-34) (SEQ ID NO: 2), 50 mg mannitol, 2.5 mg m-cresol, 0.52 mg acetic acid and 0.12 mg sodium acetate were mixed in 1 ml distilled water.

Embodiment 2

[0045] 0.25 mg rhPTH(1-34) (SEQ ID NO: 2), 45.4 mg mannitol, 3 mg m-cresol, 0.41 mg acetic acid and 0.1 mg sodium acetate were mixed in 1 ml distilled water.

[0046] The formulations of Examples 1 and 2 according to the invention were compared to solutions without stabilizers, 0.9% NaCl, 20 mM acetate and 10 mM acetate as primary stabilizers. Stability was determined by determining the percentage of the amount of rhPTH(1-34) (SEQ ID NO: 2) that remained over time. Assay by HPLC. The results are shown in Tables 1 and 2.

[0047] water

[0048] 20mM acetate

Embodiment 3

[0050] The following experiments were performed to show that lyophilized powder formulations prepared from the stabilizing solutions of the present invention were more stable than controls prepared with PTH(1-34) and mannitol alone.

[0051] The control solution and sample A to O solutions were prepared as described above, and their components and contents are shown in Table 3. The solution was then lyophilized and the resulting lyophilized powder formulation was stored at 40°C for one month. Then, the content of PTH(1-34) retained in each sample was determined by HPLC. The results are shown in Table 3.

[0052] sample

[0053] * Stability was 96% at 2 months.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing parathyroid hormone. More specifically, the present invention relates to stable solution formulations of teriparatide, PTH(1-34). Background of the invention [0002] Parathyroid hormone (PTH) is an 84 amino acid product secreted by the mammalian parathyroid gland that controls serum calcium levels through actions on various tissues including bone. Studies in humans of certain forms of PTH have demonstrated anabolic effects on bone, raising considerable concerns about their use in the treatment of osteoporosis and related bone diseases. [0003] Using the N-terminal 34 amino acids of the bovine and human hormones, which all published reports consider biologically equivalent to the full-length hormone, it has been demonstrated that when parathyroid hormone is administered subcutaneously in a pulsatile manner , parathyroid hormone especially promotes bone growth. A slightly diffe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/08A61K9/00A61K9/19A61K38/22A61K38/29A61K47/10A61K47/14A61K47/26
CPCA61K38/29A61K47/10A61K47/26A61K9/0019A61K9/19A61P19/00A61P19/10
Inventor 常亲明亨利·A·哈弗尔
Owner ELI LILLY & CO